| Product Code: ETC9946980 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market - Industry Life Cycle |
3.4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market - Porter's Five Forces |
3.5 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By Medical Condition, 2021 & 2031F |
3.7 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
3.8 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness and diagnosis rates of irritable bowel syndrome (IBS) in the United Kingdom |
4.2.2 Growing demand for effective and innovative treatments for IBS |
4.2.3 Rising healthcare expenditure and focus on digestive health in the UK |
4.3 Market Restraints |
4.3.1 Limited treatment options and lack of universally effective therapies for IBS |
4.3.2 Regulatory challenges and stringent approval processes for new IBS treatments in the UK |
4.3.3 Cost constraints and reimbursement issues for IBS medications and therapies |
5 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Trends |
6 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market, By Types |
6.1 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Lubiprostone, 2021- 2031F |
6.1.4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Linaclotide, 2021- 2031F |
6.1.5 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Eluxadoline, 2021- 2031F |
6.1.6 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Rifaximin, 2021- 2031F |
6.1.7 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Alosetron, 2021- 2031F |
6.1.8 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market, By Medical Condition |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By IBS-Constipation, 2021- 2031F |
6.2.3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By IBS-diarrhea, 2021- 2031F |
6.2.4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Mixed, 2021- 2031F |
6.3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Online Pharmacies, 2021- 2031F |
6.3.4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Clinics, 2021- 2031F |
6.4.4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenues & Volume, By Homecare Settings, 2021- 2031F |
7 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Export to Major Countries |
7.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Imports from Major Countries |
8 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Key Performance Indicators |
8.1 Patient-reported outcomes (PROs) related to symptom improvement and quality of life for IBS patients in the UK |
8.2 Adoption rates of non-pharmacological interventions, such as dietary changes and lifestyle modifications, for managing IBS in the UK |
8.3 Healthcare provider satisfaction and adherence to clinical guidelines for IBS management in the UK |
9 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market - Opportunity Assessment |
9.1 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By Medical Condition, 2021 & 2031F |
9.3 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
9.4 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market - Competitive Landscape |
10.1 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Irritable Bowel Syndrome (IBS) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here